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Abstract 
 
Objectives: Omega (n)-3 and n-6 polyunsaturated fatty acids (PUFA) are molecular modulators of 
neurotransmission and inflammation. We hypothesized that plasma concentrations of n-3 PUFA would 
be lower and of n-6 PUFA higher in subjects with bipolar disorder (BD) compared to healthy controls 
(HC), and would correlate with symptom severity in subjects with BD, and that effective treatment 
would correlate with increased n-3 but lower n-6 PUFA levels. Additionally, we explored clinical 
correlations and group differences in plasma levels of saturated and monounsaturated fatty acids.  
 
Methods: This observational, parallel group study compared biomarkers between HC (n = 31), and 
symptomatic subjects with BD (n = 27) when ill and after symptomatic recovery (follow-up). Plasma 
concentrations of five PUFA [linoleic acid (LA), arachidonic acid (AA), alpha-linolenic acid (ALA), 
docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA)], of two saturated fatty acids (palmitic 
acid and stearic acid) and of two monounsaturated fatty acids (palmitoleic acid, oleic acid) were 
measured in esterified (E) and unesterified (UE) forms.  Calculated ratios included UE:E for the five 
PUFA, ratios of n-3 PUFA (DHA:ALA, EPA:ALA, EPA:DHA), and the ratio of n-6:n-3 AA:EPA.   Comparisons 
of plasma fatty acid levels and ratios between BD and HC groups were made with Student t-tests, 
between the BD group at baseline and follow-up using paired t-tests. Comparison of categorical 
variables was performed using Chi-square tests.  Pearson’s r was used for bivariate correlations with 
clinical variables, including depressive and manic symptoms, current panic attacks, and psychosis.  
 
Results: UE EPA was lower in BD than HC, with a large effect size (Cohen’s d = 0.86, p < 0.002), however, 
it was not statistically significant after correction for multiple comparisons.  No statistically significant 
difference was seen in any plasma PUFA concentration between BD and HC after Bonferroni correction 
for 40 comparisons, at p < 0.001. Neither depressive severity nor mania severity was correlated 
significantly with any PUFA concentration. Exploratory comparison showed lower UE:E EPA in BD than 
HC (p < 0.0001).  At follow-up in the BD group, UE, E DHA:ALA, and UE EPA:ALA were decreased (p < 
0.002).  Exploratory correlations of clinical variables revealed that mania severity and suicidality were 
positively correlated with UE:E EPA ratio, and that several plasma levels and ratios correlated with panic 
disorder and psychosis. Depressive severity was not correlated with any ratio. No plasma fatty acid level 
or ratio correlated with self-reported n-3 PUFA intake or use of medication by class. 
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Conclusions: A large effect size of reduced UE EPA, and a lower plasma UE:E concentration ratio of EPA 
in the symptomatic BD state may be an important factor in vulnerability to a mood state. Altered n-3 
PUFA ratios could indicate changes in PUFA metabolism concurrent with symptom improvement. Our 
findings are consistent with preclinical and postmortem data and suggest testing interventions that 
increase n-3 and decrease n-6 dietary PUFA intake.   
 
Key words: bipolar disorder – eicosapentaenoic acid
 
 – inflammation – omega-3  
Bipolar disorder (BD) is an episodic illness affecting 1.0–4.4% of the population (1). It is a highly heritable 
polygenic disorder (2), which has a complex, incompletely understood etiology (3).  BD type I is 
characterized by manic episodes of elevated mood, energy and cognition, and by major depressive 
episodes of lowered mood, energy and cognition. BD type II is characterized by hypomanic episodes of 
less severity than manic episodes, and by major depressive episodes that are often longer and more 
difficult to treat than BD type I (4-7). Improvements in acute and maintenance treatments are needed to 
prevent relapses and reduce burden of disability. 
 
Alterations of metabolism of lipids and resultant changes in cell signaling pathways have been 
hypothesized to perturb neurotransmitter systems in mood disorders (8, 9). Arachidonic acid [(AA) 
20:4n-6] and docosahexaenoic acid [(DHA) 22:6n-3] are polyunsaturated fatty acids (PUFA) that 
compose over 90% of essential fatty acids in the mammalian brain (10). AA and DHA are derived from 
the diet or are synthesized in the liver from their respective, nutritionally essential, shorter-chain PUFA, 
linoleic acid [(LA) 18:2n-6] and alpha-linolenic acid [(ALA) 18:3n-3].  AA, DHA, and their metabolites 
function as intracellular second messengers during neurotransmission and as modulators of 
neuroinflammation and other pathological processes (8, 11). 
 
Finding common changes in neurobiological systems among effective mood stabilizing medications, 
proven effective in Phase III trials, is a potential window into understanding etiological and treatment 
mechanisms in BD.  One suggested common mechanism of action of mood stabilizers, derived from pre-
clinical studies, is downregulation of brain AA metabolism (12-14). Epidemiological and clinical data 
support the hypothesis that altered PUFA metabolism is present in BD, including reduced n-3 PUFA 
metabolism (15-21).  
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We hypothesized that plasma concentrations of n-3 PUFA would be lower and plasma concentrations of 
n-6 PUFA would be higher in subjects with BD who experience manic or depressive symptoms than in 
healthy controls (HC), and that n-3 PUFA would increase and n-6 PUFA decrease after naturalistic 
treatment.  We also hypothesized that lower n-3 and higher n-6 PUFA concentrations would be 
associated with manic and depressive symptoms, regardless of medication status.  To test these 
hypotheses, we studied subjects with BD who were in a symptomatic episode while on medication.   
 
In an exploratory analysis, we investigated associations between plasma n-3 and n-6 PUFA 
concentrations and clinical symptoms of panic, psychosis, and suicidality.  We measured both 
unesterified (UE) and esterified (E) concentrations of nine fatty acids in plasma.  We studied plasma 
concentrations because the UE form of the PUFA passes through the blood-brain barrier into brain more 
readily than does the E form (22, 23); thus the UE plasma concentration is the major peripheral form 
that represents PUFA metabolism in brain.  
 
Methods 
 
Participants and measures 
 
Participants were recruited when presenting for care during mood episodes at the Pennsylvania 
Psychiatric Institute, under Institutional Review Board Protocol No. 39164EP and NIH Office of Human 
Subject Research Exemption #11509 (7/16/2012). Participants were screened and consented for the 
study.  Patients with BD (i.e., bipolar disorder type I and bipolar disorder type II) and HC with no 
personal or family history of mood or psychotic disorder were included.  Exclusion criteria included daily 
use of anti-inflammatory medications, active substance intoxication or withdrawal, or pregnancy. The 
Mini Neuropsychiatric Interview (24), a DSM-IV-TR-based structured interview, was performed, and 
current mood state was assessed with the Hamilton Depression Rating Scale-21 (HDRS) plus Atypical 
(25) and the Clinician-Administered Rating Scale for Mania (CARS-M) (26).  Subjects completed rating 
scales including a Food Frequency Questionnaire (FFQ) for assessment of intake of n-3 PUFA (27).  
Demographic variables of interest included age and sex.  Clinical variables of interest included 
depression severity (HDRS-21 + Atypical) and mania severity (CARS-M).  Use of tobacco by smoking in 
the past month, alcohol use in the past month above recommended sex-specific limits (as 
recommended by the National Institute of Alcohol Abuse and Alcoholism: men, > 14 drinks/week or four 
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drinks per occasion, and women, > 7 drinks/week or three drinks per occasion) were recorded from 
subject response (28).  Use of antidepressant, antipsychotic, or mood-stabilizing medications was 
recorded from subject response.  Height and weight were measured and recorded.   Clinical features of 
illness including presence of current panic disorder, current suicidality, and current psychosis were 
obtained from the relevant MINI modules.  Current suicidality accounted for history of suicidal attempts, 
and current intent and plan.  A dietary report of ALA, DHA, and EPA was calculated from self-reported 
intake of omega-3 rich foods recorded on the FFQ.  
 
Subjects were followed and treated as usual.  At the start of the study, subjects were taking mood 
stabilizers (n = 21, 78%: lithium n = 14, carbamazepine n = 3, valproic acid n = 3, and lamotrigine n = 3), 
antipsychotics (n = 15, 56%: aripiprazole n = 1, haloperidol n = 2, risperidone n = 6, quetiapine n = 6, 
perphenazine n = 1, and olanzapine n = 2), antidepressants (n = 13, 48%), and/or sedatives (n = 17, 63%).  
At follow-up, subjects were taking mood stabilizers (n = 9, 69%: lithium n = 4, carbamazepine n = 1, 
valproic acid n = 1, and lamotrigine n = 1), antipsychotics (n = 7, 54%: aripiprazole n = 2, risperidone n = 
3, perphenazine n = 1, and olanzapine n = 2), antidepressants (n = 4, 31%), and/or sedatives (n = 6, 46%).  
After discharge from the hospital, subjects were followed each week by phone and assessed for clinical 
improvement.  A return visit was scheduled with repeat measures when the subject was asymptomatic, 
or after three months had elapsed. However, due to irregular contact with some subjects, the maximum 
number of days for follow-up was 187 (median length of follow-up = 22 days, mean length of follow-up = 
52 days).   
 
Sample collection and biochemical analysis 
 
Participants fasted for at least six hours, and blood was drawn in vacutainers containing EDTA for 
biomarkers in the AM. After centrifugation for 10 min at 3000 rpm, the plasma supernatant was 
transferred to plastic tubes and maintained at -80°C or on dry ice until processed.  Samples were 
processed for fatty acids after thawing in a blinded fashion at the Brain Physiology and Metabolism 
Section, NIA.   
 
Each plasma sample (0.5 mL) was extracted using the method described by Folch et al. (29) and Sublette 
(17). The plasma was mixed with a partition system of 3.0 mL chloroform:methanol (2:1) and extracted 
with 0.6 mL 0.1 M KCl. Organic extracts were concentrated under N2 at 45°C, and then suspended in 
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0.5 mL chloroform. Standards and samples were applied to Silica gel 60 TLC plates and the lipids were 
separated using heptane:diethyl ether:acetic acid (60:40:3) (30). Plates were sprayed with 0.03% TNS (6-
p- toluidine-2-naphthalene sulfonic acid) in 50 mM Tris buffer (pH 7.4) and lipid bands were visualized 
under UV light. Bands corresponding to UE fatty acids were scraped off and then directly methylated 
using 1% H2SO4
31
 in methanol (v/v) and fatty acid methyl esters (FAMEs) were extracted with heptane 
( ). Prior to methylation, heptadecanoic acid (17:0) was added as an internal standard. For E fatty acid 
determinations, 50 μL plasma extract was concentrated under N2
32
 at 45°C, then directly methylated as 
above. FAMEs were separated using a gas chromatograph (GC) (Model 6890 N; Agilent Technologies, 
Palo Alto, CA, USA) with a capillary column (SP 2330, 30 m × 0.32 mm i.d.; Supelco, Bellefonte, PA, USA) 
and a flame ionization detector ( ). Plasma fatty acid concentrations (nmol/mL) were calculated by 
direct proportional comparison of GC peak areas with that of the added 17:0 internal standard. 
 
Data and statistical analysis 
 
SPSS version 20, IBM SPSS Statistics was used for all statistical calculations. Values of continuous 
variables were compared between BD and HC groups using two-sample t-tests, and categorical variables 
were compared using the Pearson chi-square test.  Paired t-tests were used for baseline and follow-up 
measurements.   
 
Hypothesis-driven analysis. Outcome variables included the E and UE plasma forms of five PUFA, 
including LA, AA, ALA, DHA, and eicosapentaenoic acid (EPA, 22:5n-3). Comparisons of (i) plasma fatty 
acid levels were made between the BD and HC groups using Student t-tests, (ii) between BD baseline 
and follow-up of plasma fatty acid concentrations using paired t-tests, and (iii) Pearson’s r correlations 
between mean PUFA concentrations and mania severity, and between mean PUFA concentrations and 
depression severity, also were performed. Thus, 40 comparisons were investigated in a hypothesis-
driven manner.  An alpha = 0.05/40 = 0.001
 
 
was used as a significance level for these comparisons. 
In an exploratory analysis, comparisons were made between the BD and HC groups, and between 
baseline and follow-up of plasma concentrations in the UE and E forms of the saturated fatty acids, 
palmitic acid (16:0) and stearic acid (18:0), and of the monounsaturated fatty acids, palmitoleic acid 
(16:1 n-7) and oleic acid (18:1 n-9).  Additionally, the ratios of UE to E concentrations of the five PUFA 
were calculated to determine the relations between unbound to bound forms; the unbound form 
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crosses the blood-brain barrier more easily (22, 23).  Ratios of n-3 PUFA concentrations to each other 
(DHA to ALA, EPA to ALA and EPA to DHA) in the UE and E forms were constructed to estimate 
progression in the n-3 metabolism pathway. The UE and E AA:EPA ratios were calculated to estimate the 
n-6/n-3 ratio, an indication of the balance of the overall body PUFA cascade and their bioactive 
metabolites involved in neurotransmission and the resolution of inflammation (11, 33, 34). All calculated 
ratios were compared between the HC and BD groups, and between baseline and follow-up. 
 
Additional exploratory analysis was used to investigate associations between demographic and clinical 
variables and the fatty acid concentrations and ratios described above.  Pearson’s r was used for 
bivariate correlations.  Bivariate correlations were made between the fatty acid UE to E concentration 
ratios and n-3, n-3/n-6 ratios described above and the following demographic and clinical variables: age, 
sex, depression severity (HDRS-21 + Atypical), mania severity (CARS-M), smoking (past month), alcohol 
(use in the past month above recommended guidelines), current panic disorder (MINI), current 
suicidality (MINI), dietary report of ALA, DHA and EPA (FFQ), and use of antidepressant, antipsychotic or 
mood-stabilizing medications.  
 
Results 
 
Demographic and clinical description of the sample  
 
A cohort of 27 patients with BD was recruited while in a symptomatic mood episode, and a parallel HC 
group was recruited for this study.  Patients with BD had an average of 35 years at entry to the study 
and did not differ in age, gender distribution, race, or ethnicity from the HC group (n = 31) (Table 1).  The 
subjects with BD were less likely to be married, and less likely to be employed or a student than the HC 
group (Table 1).   
 
The subjects with BD were significantly heavier than the HC subjects, with a mean body mass index 
(BMI) in the obese range [BD: 30.5 (6.0), HC: 24.9 (4.7); p = 1.7 × 10
-4
). At baseline, the BD group had a 
severe level of depressive symptoms [mean HDRS-21 + Atypical questions = 34.4 (14.5)] and a moderate 
level of manic symptoms [mean CARS-M = 15.3 (12.5)].  Severity of manic and depressive symptoms was 
significantly reduced at follow-up compared with entry [mean HDRS-21 + Atypical = 9.00 (8.98), p < 0.01; 
mean CARS-M 3.46 (5.36), p = 0.01]. However, more than 50% of the subjects with BD were lost to 
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follow-up.  Many subjects had an unstable living situation upon discharge from the hospital and this may 
have contributed to poor follow-up.  Self-report of n-3 EPA, DHA, or ALA consumption using the FFQ did 
not differ between the HC and BD groups at baseline [EPA HC: 0.03 (0.03), BD: 0.03 (0.04), p = 0.88; DHA 
HC: 0.06 (0.07), BD: 0.04 (0.06), p = 0.36; ALA HC: 0.33 (0.50), BD: 0.32 (0.65), p = 0.96]; or in the BD 
group from baseline (BL) to follow-up (FU): [EPA BD BL: 0.02 (0.03), BD FU: 0.02 (0.03), p = 0.28; DHA BD 
BL: 0.04 (0.05), BD FU: 0.04 (0.05), p = 0.22; ALA HC: 0.28 (0.64), BD: 0.28 (0.23), p = 0.83].   
 
The subjects with BD predominantly were diagnosed with bipolar disorder type I (n = 21, 78%) and a 
smaller number were diagnosed with bipolar disorder type II (n = 6, 22%).  About one-half of the 
subjects with BD had psychosis with the current episode, the majority (n = 22, 82%) had suicide risk, and 
19% (n = 5) had current panic disorder.  At the time of assessment, more than one-half of the BD sample 
smoked (n = 14, 56%), 15% (n = 4) drank above the sex-specific recommended limit within the month 
prior to assessment, and 39% (n = 10) used an illicit drug within the month prior to assessment.  At 
baseline presentation, 78% (n = 21) of the BD subjects were taking mood-stabilizing medication, 48% (n 
= 13) were taking antidepressants, and 56% (n = 15) were taking antipsychotic medication.  Treatment 
was not controlled for this study, and on follow-up, 69% of the subjects were taking a mood-stabilizing 
medication, 54% were taking an antipsychotic, and 31% were taking an antidepressant.   
 
We report our results below categorized by fatty acid or fatty acid group.  Unesterified (UE) forms of the 
FA were measured because they are better able to cross the blood-brain barrier (22, 23), and a 
difference in the UE:E ratio may signal a difference in availability of the PUFA to the brain, or a slowed 
production of the UE from the E plasma PUFA due to hydrolysis by circulating or tissue lipases.  
 
Plasma n-3 concentrations, UE:E ratios, n-3 ratios, and clinical correlations 
 
EPA. The mean concentration of UE EPA was lower in the BD than HC group.  Although the effect size 
was large (Cohen’s d = 0.86), the difference bordered on statistical significance after consideration of 
multiple testing (p = 0.002, alpha set at 0.001). No statistically significant difference was found in the E 
EPA levels at baseline, nor in either form of EPA in the BD group between baseline and follow-up (Table 
1).   Neither mania nor depression severity correlated with UE or E EPA plasma concentrations at 
baseline in the BD group.  
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Exploratory analysis revealed that at baseline, the mean ratio of UE:E EPA was significantly lower in the 
BD than HC group (Table 2 and Fig. 1)  (p = 9 × 10
-5
 
), but did not differ between BD at baseline or follow-
up.  
Significant exploratory clinical correlations for U or E EPA or UE:E EPA ratios included a positive 
correlation between age and a higher mean UE EPA concentration (r = 0.46, p = 0.02).  Panic attacks and 
suicidality correlated negatively and significantly with mean UE EPA plasma concentrations (panic 
attacks: r = -0.41, p = 0.03; suicidality: r = -0.49, p = 0.009).  However, mania was positively correlated 
with the UE:E EPA ratio (mania: r = 0.51, p = 0.006).  
 
DHA. No significant difference was found between UE or E DHA plasma concentrations in the BD and HC 
groups at baseline or between BD group at follow-up and baseline, using an adjusted alpha for multiple 
testing (p = 0.001) (Table 2).  Neither mania nor depression severity correlated with UE or E DHA plasma 
concentrations at baseline in the BD group. 
 
Exploratory analysis revealed no differences in mean ratios of UE:E DHA at baseline, nor between BD at 
baseline or follow-up (Table 2).  
 
Significant exploratory clinical correlations for U or E DHA or UE:E DHA included a positive correlation 
between panic attacks and UE DHA (r = 0.46, p = 0.02), and between panic attacks and UE:E DHA (r = 
0.42, p = 0.03).  
 
ALA.  No significant difference was found between UE or E ALA plasma concentrations in the BD and HC 
groups at baseline or between BD group at follow-up and baseline, using an adjusted alpha for multiple 
testing (p = 0.001) (Table 2).  Neither mania nor depression severity correlated with UE or E ALA plasma 
concentrations at baseline in the BD group. 
 
Exploratory analysis revealed no differences in mean ratios of UE:E ALA at baseline, nor between BD at 
baseline or follow-up (Table 2).  
 
Significant exploratory clinical correlations for U or E ALA or UE:E ALA included a negative correlation 
between psychosis and E ALA (r = -0.46, p = 0.03).  
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N-3 ratios (DHA:ALA, EPA:ALA, EPA:DHA) 
 
Differences in the ratios of n-3 species between BD and HC, and BD at baseline and follow-up were 
tested in an exploratory fashion (Table 2). No group difference was found at baseline in the three ratios. 
At the follow-up time point, investigation of PUFA ratios revealed the UE EPA:ALA was decreased 
significantly (p = 0.002), and the UE EPA:DHA increased significantly (p = 0.03).  Additionally, the E and 
UE DHA:ALA both decreased significantly (p ≤ 0.001).   
 
Clinical correlations with these ratios revealed that panic attacks correlated negatively and significantly 
with the EPA:DHA ratio (r = -0.40, p = 0.04), and panic attacks were positively correlated with UE 
DHA:ALA (r = 0.47, p = 0.01). 
 
Plasma n-6 PUFA concentrations and clinical correlations 
 
No significant difference was found between UE or E LA or UE or E AA concentrations in the BD and HC 
groups at baseline or between BD group at follow-up and baseline using an adjusted alpha for multiple 
testing (p = 0.001) (Table 3).  There were no significant correlations between UE or E LA, or UE or E AA 
and mania or depression severity.   
 
In exploratory analysis, group differences in the UE:E LA significantly decreased between follow-up and 
baseline in the BD group that completed follow-up (Table 3). 
 
Investigation for clinical correlations revealed that panic attacks were significantly positively correlated 
with UE AA (r = 0.43, p = 0.03) and mean UE:E ratios of LA (r = 0.42, p = 0.03) and of AA (r = 0.44, p = 
0.02). Psychosis was negatively correlated with E LA (r = -0.45, p = 0.02). 
 
N-6 to n-3 ratio and clinical correlations 
 
The mean ratio of E AA:EPA was significantly lower in BD compared to HC (Table 3) (p = 0.005). There 
was a medium effect size difference of 0.46 calculated by Cohen’s d in the group difference between HC 
and BD of UE:E AA:EPA, but the difference was not statistically significant (p = 0.10). Panic (r = 0.59, p = 
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0.001) and psychosis (r = 0.43, p = 0.03) were significantly and positively correlated with UE AA:EPA 
ratio. 
 
Saturated and monounsaturated fatty acids 
 
No significant difference was found in saturated or monounsaturated fatty acid concentrations between 
BD and HC at baseline, or in BD between follow-up and baseline (see Supplementary Table S1).  Panic 
attacks were positively correlated with mean concentrations of several UE fatty acids, including palmitic 
(r = 0.46, p = 0.03), palmitoleic (r = 0.46, p = 0.02), and oleic (r = 0.44, p = 0.022) acids. Psychosis was 
negatively correlated with mean E concentrations of palmitic (r = -0.53, p = 0.004) and stearic (r = -0.44, 
p = 0.02) acids.  
 
 
Clinical correlations with PUFA concentrations and ratios were explored with age, sex, smoking, alcohol, 
current panic disorder, current suicidality, and use of antidepressant, antipsychotic, or mood-stabilizing 
medications.  No fatty acid level or ratio correlated significantly with sex (p > 0.07), depression (p > 
0.14), smoking (p > 0.06), or alcohol use (p > 0.07).  There was no significant correlation between any 
fatty acid level and use of a medication class (antidepressant p > 0.24, mood stabilizer p > 0.12, or 
antipsychotic p > 0.08).  
 
Discussion 
 
We determined differences in plasma concentrations and ratios of nine esterified (E) and unesterified 
(UE) long-chain fatty acids, five of which were PUFAs, between 27 BD patients and 31 HC.  Two PUFAs 
belonged to the n-6 series, AA and its nutritionally essential shorter-chain precursor LA, three to the n-3 
series, EPA, DHA, and their nutritionally essential shorter chain precursor ALA (illustrated in Fig. 2).   
 
Based on the literature, we hypothesized that (i) plasma concentrations of n-3 PUFA would be lower and 
concentrations of n-6 PUFA would be higher in patients with BD with manic or depressive symptoms; (ii) 
n-3 PUFA would increase and n-6 PUFA decrease after naturalistic treatment of the patients; and (iii) 
lower n-3 and higher n-6 PUFA concentrations would be associated with manic and depressive 
symptoms, regardless of medication status.  
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After correcting for 40 comparisons, we did not find a significant difference between the plasma E or UE 
concentration of any of the fatty acids, although the effect size indicating a reduced EPA in BD compared 
with HC was high and the p-value was 0.002, suggesting a robust effect. This suggestion is particularly 
relevant because this study should be considered exploratory in a unique patient cohort, and the 
multiple comparison restriction should be taken with reservations considering the likelihood of a Type 2 
error (35).  
 
Some evidence indicates that EPA is the active n-3 PUFA responsible for mood-altering effects in n-3 
PUFA supplementation studies of depression (36, 37). Low EPA may be a vulnerability factor to 
experiencing mood episodes, and alteration of its elongation from ALA may influence effective 
treatment.  Other studies of patients with BD also have reported reduced plasma EPA (38), and efficacy 
of nutritional supplementation with EPA (27, 39), although the issue is far from settled.  
 
EPA metabolites include bioactive cyclopentenone-IsoP molecules, termed A(3)/J(3)-IsoPs, formed by 
EPA peroxidation (40), and anti-inflammatory resolvin E1 (41).  EPA has positive effects in mitochondria 
(42), a protective effect in cardiac myocytes (43), and a regulatory effect on brain capillary tight 
junctions (44) and other capillary endothelium (45). In this regard, while unesterified EPA is largely β-
oxidized after entering rat brain, as compared with the incorporation of intact DHA into brain 
membrane phospholipids (46), EPA’s mechanism of action in BD may be at the capillary endothelium, 
which has a high mitochondrial content (47) and may be disturbed due to neuroinflammation in BD (48). 
 
Lower n-3 PUFA have been seen in a number of clinical studies of BD, particularly studies that 
investigate erythrocyte concentrations.  McNamara et al. (19) found differences in erythrocyte EPA + 
DHA levels, and three studies reported lower erythrocyte DHA in symptomatic BD groups (18, 19, 49). 
However, Sublette et al. (17) reported on plasma concentrations of UE and E PUFA, and found no 
between-group differences in UE PUFA levels or the UE AA:EPA ratio.  The critical differences may lie in 
the different methods of measuring PUFA, in the different symptomatic states of the subject 
populations, and in the different dietary intake status.    
 
While plasma PUFA concentrations may vary more over time than erythrocyte concentrations, due to 
the four-month mean life time of circulating erythrocytes, studying plasma concentrations allows us to 
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evaluate circulating UE and E PUFA separately.  Additionally, plasma concentrations reflect immediate 
consequences of changing diet and liver metabolism. Esterase activity on circulating lipoproteins 
releases UE PUFA, the form that preferably enters the brain, likely by a diffusional mechanism (50, 51).  
After entering brain, the largest percentage of UE shorter-chain PUFA (e.g. LA, ALA, EPA) is rapidly beta-
oxidized by mitochondria (38), whereas the elongated AA and DHA forms preferentially enter the sn-2 
position of brain membrane phospholipids to replace the respective PUFAs that have been hydrolyzed 
and lost by metabolism.   
 
The suggested beneficial effects of certain PUFAs may be peripheral as well as central.  Increased UE 
fatty acids triggered by fasting have been shown in rodents to drive immunosuppression (52).   
Alternately, conversion of EPA to DHA in the liver (46) may drive the treatment effect.  One intervention 
study using UE PUFA showed that administration of fish oil increased brain UE DHA and a 
neuroprotective DHA metabolite, neuroprotectin D-1, in a rodent model of Alzheimer’s disease (54).  
Additionally, phospholipase A2 
52-58
genes and enzyme levels may differ between BD and HC groups, which 
may affect production of plasma PUFA ( ).  A recent trial of n-3 PUFA for reduction of plasma 
triglycerides showed a phospholipase A2 59 genotype x treatment interaction ( ). Therefore investigation 
of UE and E PUFA provides a different window of investigation than of PUFA within RBC membrane, into 
the role of PUFA metabolism in BD.   
 
Changes at follow-up in n-3 PUFA metabolism  
 
We engaged participants during an active mood episode, and monitored symptoms during recovery, 
asking them to return when they no longer met threshold criteria for mania and depression.  Treatment 
was not altered from usual care during this time.  During this follow-up period, we lost approximately 
half of our participants due to inability to contact them.   Therefore, our results in investigative 
comparisons between baseline and follow-up are exploratory and only suggestive due to the small 
sample size.  We found no difference in plasma levels of PUFA when comparing mean baseline 
concentrations to concentrations at follow-up, however ratios of some plasma n-3 PUFA concentrations 
were significantly different at follow-up from baseline in BD subjects.  There was no change in self-
reported n-3 PUFA intake at follow-up. The ratio changes indicate decreases in UE DHA relative to UE 
ALA, in UE EPA relative to UE ALA, and in E DHA relative to E ALA.  Since ALA once ingested can be 
elongated and desaturated, particularly in the liver, first to EPA and then to DHA (60), these results 
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suggest some limitation to these metabolic conversions. One possibility is drug effects on the liver (61).  
Though we cannot comment on mechanism from our data, the ratio data suggest abnormal metabolic 
relations among the three measured n-3 PUFAs.   
 
Symptom and clinical correlations with fatty acid levels and ratios  
 
Symptom severity has been correlated with circulating PUFA biomarkers in the Sublette et al.(17) and 
Evans et al. (20) studies, but not in the Chiu et al. (18) and McNamara et al. (19) studies.  Sublette et al. 
found a positive correlation between manic symptoms and the UE AA:EPA ratio.  In our study, however, 
the UE AA:EPA ratio was not correlated with mania, but was positively correlated with psychosis.   Two 
factors that could affect this ratio differed in our trial from the Sublette trial, including the symptomatic 
state of our subjects (we had few subjects with pure mania in our study), and including patients 
currently on psychiatric medication.  We found the UE:E ratio of EPA was positively correlated with 
mania, which would not be expected given that a lower UE:E EPA was found in BD compared to HC. This 
will bear further investigation.   
 
In our study, subjects with panic attacks as part of the current mood episode showed lower n-3 and 
higher n-6 concentrations, and a higher n-6 to n-3 ratio.  This pattern suggests activation of an 
inflammatory pathway or reduction of an anti-inflammatory pathway. The noradrenergic surge seen in 
panic attacks has been hypothesized to be related to the dopaminergic surge seen in mania in BD, and 
perhaps panic identifies a subset of mania or is a severity marker of psychiatric illness (62-65).  Together, 
ours and others’ findings suggest an altered PUFA metabolism in BD, in accord with pre-clinical data. 
 
We found a positive correlation between UE saturated fatty acids and panic, and a negative association 
between E saturated fatty acids and psychosis.  The differentiating factor may be the esterification 
status, as the UE form preferentially enters brain. UE palmitic acid was shown to increase anxiety-like 
behaviors and immunosuppression in rodent models (66, 67).  UE fatty acids may be associated with 
clinical phenotype through an immunological link.  
 
Medication status 
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While both Sublette et al. (17) and McNamara et al. (19) studied PUFA in un-medicated patients, the 
Chiu et al. study (18) found no difference between un-medicated and medicated patients.  Our approach 
differed, as we studied relations between effective treatment and biological markers. We included 
patients who were ill though medicated, and those with comorbid psychiatric illness, specifically looking 
for differences before and after treatment.  We had no un-medicated subjects in our sample, but we did 
not find that concentrations or ratios of PUFA were correlated with antidepressant, antipsychotic, or 
mood stabilizers as medication groups.   
 
Dietary report  
 
We found no correlations between self-report of ALA, EPA, and DHA intake and plasma fatty acid levels, 
which could occur for several reasons.  The subjects in this study may have been unable to accurately fill 
out the questionnaire given the severity of mood symptoms.  A more controlled dietary regimen would 
be useful in this regard (68). Additionally, individual metabolic differences may mask correlations with 
reported intake.  The memory difficulty inherent in mood episodes may have interfered with the ability 
to report food intake accurately.  Further study with this instrument would be beneficial to understand 
barriers to its use.  
 
Limitations 
 
Limitations include the use of patients who are taking medication in a study of biomarkers.  While the 
heterogeneity of the subjects with BD with regard to medication use at baseline, in follow-up and 
comorbid psychiatric illness may limit the precision with which the findings of PUFA differences can be 
related to bipolar neuropathology, this study design maximizes the generalizability of the findings to a 
real-world clinical population.  
 
If EPA metabolism differs in patients who are symptomatic and is altered with successful treatment, 
regardless of the medication class, this suggests that effective medications in practice have a similar 
biological impact on the n-3/n-6 metabolic balance, mirroring pre-clinical findings (12).  Additionally, our 
results at follow-up are only suggestive, as (i) treatment was not delivered as a controlled intervention, 
and (ii) less than 50% of the sample completed the follow-up.  While baseline factors did not differ 
between the groups that did or did not follow-up, we could not measure treatment response in those 
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who did not complete the study.  The patients had a high rate of unstable housing and contact 
information, which may have been a factor in their inability to complete the study.  Other limitations 
include self-report of dietary n-3 input only.  Baseline dietary intake of PUFA may indeed influence 
response of the system to intervention. In addition, this study was not large enough to look for 
subgroups of subjects who may have PUFA alterations, while others may not.  
 
Conclusions 
 
We found (i) a lower plasma UE:E concentration ratio of EPA, (ii) a trend toward lower U EPA in the 
symptomatic BD state, and (iii) altered n-3 PUFA ratios upon follow-up in a subset of the BD sample.   
Altered plasma circulating n-3 PUFA concentrations may influence vulnerability to a mood state, and 
altered n-3 PUFA ratios could indicate changes in PUFA metabolism concurrent with symptom 
improvement. Panic attacks, which may be a marker of clinical severity, were correlated with lower n-3 
and higher n-6 PUFA concentrations and a higher n-6 to n-3 ratio.  Our findings are consistent with 
preclinical and postmortem data and suggest testing interventions that increase n-3 and decrease n-6 
dietary PUFA intake.   
 
Implications  
 
While initial n-3 PUFA supplementation studies in BD demonstrated efficacy in open trials (69-72), and 
subsequent randomized controlled trials (73, 74) failed to replicate these findings (75-79), preclinical 
and post-mortem data implicate PUFA in pathophysiology of BD (12, 13).  Interpretation of the varied 
responses seen in randomized, controlled trials is confounded by a number of factors, including 
heterogeneity of diagnosis, design of trials, compliance to study drug, and composition and dose of 
supplements (36, 80-84).    
 
One reason that supplement studies may have not shown effect may be that in the past century, the n-6 
PUFA precursor LA has increased in the average US diet, resulting in decreasing tissue concentrations of 
n-3 EPA and DHA and increasing concentrations of AA and LA and their metabolites (85–87).  Addition of 
an n-3 supplement without concurrent reduction in dietary n-6 LA may not produce clinically meaningful 
benefit. A recent randomized trial investigated PUFA dietary intervention in chronic migraine headache, 
a condition with considerable overlap with BD in pathophysiology, comorbidity, and treatment (34, 88-
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101).  Clinical efficacy and biochemical effects of a high n-3 EPA + DHA plus low n-6 LA (H3-L6) diet were 
compared to a low n-6 PUFA diet (L6).  The H3-L6 group experienced a significantly greater reduction in 
headache hours per day, headache days per month, headache-related quality-of-life and psychological 
distress than the L6 group, though both groups experienced improvement from the run-in phase (68).  
Interestingly, both the L6 and the H3-L6 groups had increases in UE EPA, specifically, among PUFA (102).  
Based on the clinical and neuroinflammatory links between BD and migraine, concurrent lowering of 
dietary n-6 in BD may also be necessary for effective treatment of bipolar disorder with n-3 PUFA 
supplementation (103). Future studies of the specific signaling pathways and lipid mediators linking n-3 
and n-6 PUFA to BD pathogenesis may lead to development of targeted dietary and medication 
strategies for treating BD. 
 
Figure legends 
 
Fig. 1. At baseline, the mean ratio of unesterified (UE) to esterified (E) concentration of 
eicosapentaenoic acid (EPA) was significantly lower in the bipolar disorder group when compared to the 
healthy control group. CI = confidence interval. 
 
Fig. 2. The metabolic pathway of the polyunsaturated fatty acids linoleic acid (the n-6 pathway) and 
alpha-linoenic acid (the n-3 pathway) to arachidonic acid (AA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA).  
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Table 1. Demographics  
 
 Healthy controls 
(n = 31) 
Bipolar disorder 
(n = 27)
a
p-value  
  
Sex, female, n (%) 18 (60) 12 (44) 0.30 
Race, n (%)    
   Asian 4 (13) 0 (0) 0.19 
   Black 1 (3) 1 (3.7)  
   White 26 (84) 25 (93)  
   Mixed 0 (0) 1 (3.7)  
Ethnicity, n (%)   0.18 
  Hispanic  2 (6) 0 (0)  
  Not Hispanic 29 (94) 27 (100)  
Marital status, n (%)   0.03 
  Married 16 (52) 5 (19)  
  Separated 1 (3) 1 (3)  
  Divorced 0 (0) 3 (11)  
  Never married 14 (46) 18 (67)  
Employment, n (%)   < 0.01 
   Unemployed 2 (6) 14 (54)  
   Disabled 0 (0) 5 (19)  
   Employed 17 (55) 6 (23)  
   Student 11 (36) 1 (4)  
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   Retired 1 (3) 0 (0)  
Smoking, n (%) 1 (3) 14 (56) NA 
Heavy alcohol use, n (%) 1 (3) 4 (15)  
Drug use, n (%) 1 (3) 10 (39)  
Suicidality, n (%) 0 (0) 22 (82)  
Psychosis, n (%) 0 (0) 14 (52)  
Panic, n (%) 0 (0) 5 (19)  
Age, years, mean (SD) 32 (11) 35 (11) 0.31 
BMI, mean (SD) 24.9 (4.7) 30.5 (6.0) 1.7 × 10
-4
 
Mania (CARS-M), mean (SD) 15.3 (12.5) 0 (0)  
Depression (HDRS-21 + Atypical), 
mean (SD) 
34.4 (14.5) 0.3 (0.6)  
 
SD = standard deviation; BMI = body mass index; CARS-M = Clinician-Administered Rating Scale for Mania; 
HDRS = Hamilton Depression Rating Scale-21. 
 
a
 
At baseline. 
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Table 2.  N-3 polyunsaturated fatty acid plasma concentrations and ratios in the bipolar disorder and healthy control groups at 
baseline and follow-up (nmol/mL) 
 
 
 
Baseline 
 
 
Bipolar disorder, follow-up 
  
 Healthy controls 
(n = 31) 
Bipolar disorder 
(n = 27) 
p-value Baseline 
(n = 13) 
Follow-up 
(n = 13) 
p-value 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
ALA       
   E 19.89 (25.64) 18.86 (12.81) 0.85 18.48 (17.30) 25.45 (15.42) 0.18 
   UE 2.10 (2.80) 1.40 (1.77) 0.27 0.88 (1.06) 2.28 (1.72) 0.02 
DHA       
   E 220.93 (93.79) 221.37 (83.10) 0.99 227.46 (84.10) 177.71 (161.19) 0.28 
   UE 1.07 (0.64) 1.04 (1.04) 0.89 0.73 (0.38) 0.55 (0.26) 0.11 
EPA       
   E 8.91 (6.94) 13.91 (13.39) 0.07 14.62 (18.98) 12.68 (6.86) 0.75 
   UE 0.32 (0.18) 0.20 (0.08) 0.002 0.21 (0.06) 0.31 (0.26) 0.16 
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   ALA 0.14 (0.13) 0.08 (0.10) 0.05 0.08 (0.13) 0.12 (0.10) 0.27 
   DHA 0.006 (0.005) 0.005 (0.003) 0.34 0.004 (0.003) 0.005 (0.003) 0.32 
   EPA 0.05 (0.03) 0.02 (0.01) 9 × 10 0.02 (0.02) 
-5
 0.04 (0.07) 0.24 
DHA:ALA       
   E 18.20 (11.34) 14.27 (6.05) 0.10 16.15 (6.05) 7.44 (5.36) 0.001 
   UE 0.92 (0.86) 1.13 (0.77) 0.33 1.12 (0.43) 0.31 (0.17) 4 × 10
-5
 
EPA:ALA       
   E 0.61 (0.23) 0.71 (0.18) 0.07 0.72 (0.19) 0.54 (0.20) 0.06 
   UE  0.28 (0.18) 0.26 (0.17) 0.78 0.36 (0.17) 0.19 (0.16) 0.002 
EPA:DHA       
   E 0.05 (0.03) 0.08 (0.12) 0.13 0.09 (0.17) 0.10 (0.07) 0.86 
   UE 0.39 (0.29) 0.30 (0.21) 0.18 0.37 (0.24) 0.58 (0.29) 0.03 
 
SD = standard deviation; E = esterified; UE = unesterified; ALA = alpha-linolenic acid; DHA = docosahexaenoic acid; EPA = 
eicosapentaenoic acid. 
 
Table 3. N-6 and n-6:n-3 polyunsaturated fatty acid plasma concentrations and ratios in the bipolar disorder and healthy control 
groups at baseline and follow-up (nmol/mL)  
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 Baseline Bipolar disorder, follow-up  
 Healthy controls 
(n = 31) 
Bipolar disorder  
(n = 27) 
p-value Baseline 
(n = 13) 
Follow-up 
(n = 13) 
p-value 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
LA       
   E 2684.88 (794.62) 2624.80 (638.07) 0.75 2548.78 (724.90) 3808.82 (2030.68) 0.02 
   UE 54.07  (30.18) 62.81 (57.70) 0.48 53.45 (47.66) 36.66 (27.46) 0.07 
AA       
   E 676.94 (202.42) 720.07 (196.35) 0.42 739.90 (244.02) 950.11 (449.19) 0.03 
   UE 2.73 (1.64) 2.85 (2.15) 0.82 2.28 (1.67) 1.98 (0.84) 0.46 
UE:E       
   LA 0.02 (0.01) 0.03 (0.02) 0.39 0.02 (0.02) 0.01 (0.01) 0.02 
   AA 0.004 (0.002) 0.004 (0.003) 0.85 0.003 (0.002) 0.002 (0.001) 0.18 
AA: EPA       
   E  100.69 (55.32) 68.05 (26.48) 0.005 78.68 (31.02) 88.05 (39.86) 0.54 
   UE 10.96 (7.59) 18.59 (22.13) 0.10 11.83 (9.62) 9.65 (7.18) 0.28 
 
 
SD = standard deviation; E = esterified; UE = unesterified; LA = linoleic acid; AA = arachidonic acid; EPA = eicosapentaenoic acid.  A
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